Physician profile
John H Mitchell
NPI 1225024912
$7,010.05
in general payments reported to CMS, 2019-2025
27 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,113 · 2020: $971 · 2021: $918 · 2022: $672 · 2023: $770 · 2024: $812 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,104.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,085.29 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $905.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $639.42 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $366.80 | 2019-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $355.73 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $336.25 | 2019-2023 | Livalo |
| Allergan, INC. | $293.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.63 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $234.86 | 2019 | |
| Bausch Health US, LLC | $193.81 | 2019-2025 | Aplenzin |
| Antares Pharma, INC. | $175.35 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $170.87 | 2019-2020 | |
| Medicure Pharma INC. | $166.20 | 2019-2023 | Zypitamag |
| Glaxosmithkline, LLC. | $161.13 | 2023-2024 | Arexvy, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $154.90 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $104.00 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $99.76 | 2019 | |
| Amneal Pharmaceuticals LLC | $37.20 | 2019 | |
| Horizon Therapeutics Plc | $30.68 | 2020 | |
| Grifols USA, LLC | $20.90 | 2019 | |
| Pfizer INC. | $17.97 | 2019 | |
| Sanofi Pasteur INC. | $17.31 | 2019 | |
| Therapeuticsmd, INC. | $16.70 | 2019 | |
| Radius Health, INC. | $15.48 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.61 | 2023 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.